List of Excipients in Branded Drug MALARONE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	MALARONE	atovaquone and proguanil hydrochloride	0173-0675	CELLULOSE, MICROCRYSTALLINE
GlaxoSmithKline LLC	MALARONE	atovaquone and proguanil hydrochloride	0173-0675	FERRIC OXIDE RED
GlaxoSmithKline LLC	MALARONE	atovaquone and proguanil hydrochloride	0173-0675	HYPROMELLOSE
GlaxoSmithKline LLC	MALARONE	atovaquone and proguanil hydrochloride	0173-0675	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
GlaxoSmithKline LLC	MALARONE	atovaquone and proguanil hydrochloride	0173-0675	MAGNESIUM STEARATE
GlaxoSmithKline LLC	MALARONE	atovaquone and proguanil hydrochloride	0173-0675	POLOXAMER 188
GlaxoSmithKline LLC	MALARONE	atovaquone and proguanil hydrochloride	0173-0675	POLYETHYLENE GLYCOL 400

Malarone Excipient Strategy and Commercial Opportunities

Last updated: October 3, 2026

Malarone is the fixed-dose combination of atovaquone and proguanil hydrochloride used for malaria prophylaxis and treatment. Its commercial value is driven less by active-ingredient exclusivity than by formulation execution, global distribution, pediatric usability, supply reliability, and regulatory efficiency.

The core formulation challenge is atovaquone’s very low aqueous solubility and food-dependent absorption. Excipient systems that improve wetting, dispersion, tablet disintegration, dose uniformity, and palatability can support differentiated generic, pediatric, travel-health, and global-health products.

What is Malarone and how is it formulated?

Malarone combines two antimalarial agents with complementary mechanisms:

Product	Atovaquone	Proguanil hydrochloride	Primary use
Adult tablet	250 mg	100 mg	Malaria prophylaxis and treatment
Pediatric tablet	62.5 mg	25 mg	Pediatric prophylaxis and treatment

The labeled adult dose for prophylaxis is one tablet daily, beginning one or two days before entering a malaria-endemic area and continuing for seven days after leaving. Treatment generally consists of four adult tablets once daily for three consecutive days. Pediatric dosing is weight-based.[1]

The reference product uses an immediate-release tablet with a conventional excipient platform. Public labeling identifies the following inactive ingredients:

Formulation component	Function
Poloxamer 188	Wetting agent and surfactant
Microcrystalline cellulose	Diluent and compression aid
Low-substituted hydroxypropyl cellulose	Disintegrant and binder
Povidone K30	Binder
Sodium starch glycolate	Superdisintegrant
Magnesium stearate	Lubricant
Hypromellose	Film former
Titanium dioxide	Opacifier and colorant
Polyethylene glycol 400	Plasticizer
Red iron oxide or ferric oxide	Colorant

The exact inactive-ingredient declaration should be verified against the current FDA labeling and product-specific manufacturing documents before development or filing.[1,2]

What excipient properties are most important for atovaquone and proguanil?

Atovaquone is the principal formulation constraint. It has poor water solubility, and systemic exposure is materially affected by administration with food. Proguanil hydrochloride is more soluble and does not create the same dissolution burden. A formulation designed around the average behavior of proguanil can therefore underperform for atovaquone.

The highest-value excipient functions are:

1. Increasing wetting of atovaquone particles.
2. Maintaining rapid dispersion after tablet disintegration.
3. Preventing segregation between atovaquone and proguanil.
4. Preserving dissolution across manufacturing sites.
5. Improving pediatric taste and swallowability.
6. Supporting robust content uniformity at the 62.5 mg/25 mg strength.

Poloxamer 188 is strategically important because it improves wetting of hydrophobic drug particles. Sodium starch glycolate and low-substituted hydroxypropyl cellulose support rapid breakup of the tablet. Microcrystalline cellulose and povidone provide the mechanical properties needed for a relatively high-dose combination tablet.

A development team should avoid treating excipients as interchangeable commodities. Substitution can change particle wetting, granule porosity, disintegration time, dissolution, tablet hardness, and food-effect behavior.

Which formulation approaches can improve Malarone products?

Direct-compression tablets

Direct compression is commercially attractive because it reduces processing steps and avoids solvent handling. The main risks are poor flow, segregation, low tablet strength, and inconsistent dissolution caused by the high proportion of atovaquone.

A successful direct-compression platform would require tight controls on:

• Atovaquone particle-size distribution
• Bulk density and flow
• Excipient particle-size compatibility
• Blend uniformity
• Lubrication time
• Tablet porosity
• Dissolution under discriminatory conditions

Direct compression is most suitable where the active pharmaceutical ingredient has consistent physical properties and the manufacturer can maintain narrow incoming-material specifications.

Wet granulation

Wet granulation can improve flow, reduce segregation, and enhance content uniformity. It may also produce more robust tablets at lower compression force. The disadvantages are higher manufacturing complexity, possible overgranulation, and the need to control moisture exposure.

Povidone K30 can act as a binder, while sodium starch glycolate or low-substituted hydroxypropyl cellulose can be incorporated to restore rapid disintegration. Excessive binder or granule densification could slow atovaquone dissolution.

Particle engineering and micronization

Particle-size reduction is one of the most direct ways to improve atovaquone dissolution. Micronization can increase surface area, but it also increases cohesion, electrostatic charging, dusting, and blend-segregation risk.

The commercial opportunity is strongest where particle engineering is combined with a controlled surfactant system rather than used alone. Potential approaches include:

• Micronized atovaquone with poloxamer-based wetting
• Spray-dried dispersions
• Co-milled drug-excipient systems
• Amorphous solid dispersions
• Lipid-based dispersions
• Spray-congealed or fluid-bed-coated particles

These approaches may improve exposure, but they create a higher regulatory burden. Changes in solid state, crystallinity, particle morphology, and residual solvent profile can require extensive characterization.

Oral suspension or powder-for-reconstitution

A liquid product could address pediatric swallowing barriers and markets where tablet administration is difficult. The main development issues are physical stability, sedimentation, redispersibility, taste, preservative compatibility, and dose-measurement accuracy.

Atovaquone’s insolubility makes a true solution unlikely without aggressive solvent or cosolvent use. A suspension or dry powder for reconstitution is more practical. The formulation would need:

• Suspending agents
• Wetting agents
• Taste-masking agents
• Buffer control
• Preservative protection if supplied as a liquid
• A calibrated oral syringe
• Stability after reconstitution

A dry powder product has logistics advantages in tropical climates because it reduces water activity and may improve shelf life.

What pediatric excipient opportunities exist for Malarone?

The pediatric tablet has a lower drug load but retains the same fundamental problems: poor atovaquone solubility, bitter taste, and weight-based dosing.

Potential pediatric formats include:

Format	Commercial advantage	Main technical risk
Smaller film-coated tablet	Familiar regulatory path	Swallowability and dose flexibility
Chewable tablet	Easier administration	Taste masking and food-effect changes
Orally disintegrating tablet	No water required	Moisture sensitivity and dose uniformity
Powder sachet	Useful in low-resource settings	Content uniformity and palatability
Dry suspension	Flexible dosing	Reconstitution and physical stability
Dispersible tablet	Suitable for young children	Dissolution and dispersibility control

Taste masking is difficult because both the active combination and some surfactant systems may produce an unpleasant mouthfeel. Polymer coating, ion-exchange resins, lipid barriers, sweetener systems, and flavor-masking technologies are potential tools. Any taste-masked product must still release atovaquone rapidly enough to meet dissolution and bioequivalence requirements.

A dispersible tablet may offer the strongest balance between regulatory simplicity, shipping efficiency, and pediatric usability. It avoids the water and preservative problems of a liquid while permitting administration in a small volume.

What patents protect Malarone and when does it lose exclusivity?

Malarone’s active-ingredient and combination-product exclusivity has expired in the United States. Generic atovaquone/proguanil products have been approved, and the product is not dependent on current biologic exclusivity or an active small-molecule market monopoly.

The commercial position can be summarized as follows:

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Fixed-dose combination exclusivity	Expired
Pediatric exclusivity	Expired
Formulation patents	Historical protection may exist, but does not prevent ordinary generic entry
Method-of-use patents	Historical malaria-treatment and prophylaxis claims are not a current barrier to routine generic supply
Orange Book-listed blocking rights	Must be assessed against the current NDA record and active listed patents
Biosimilar exclusivity	Not applicable; Malarone is a small-molecule drug

The FDA Orange Book and current NDA record for Malarone should control any live patent or exclusivity assessment. Historical patent protection around atovaquone, proguanil combinations, formulations, and manufacturing processes does not create the same entry barrier as an unexpired composition patent.[3]

What is the Orange Book status of Malarone?

Malarone is regulated as a small-molecule drug under an FDA new drug application. The relevant commercial pathway for competitors is generally an abbreviated new drug application, provided the applicant can demonstrate pharmaceutical equivalence and bioequivalence.

Orange Book analysis should distinguish between:

• The reference listed drug
• Adult and pediatric strengths
• Approved dosage forms
• Listed patents
• Patent-use codes
• Exclusivity codes
• Generic approvals
• Discontinued or active marketing status

Atovaquone/proguanil is not a biologic, so biosimilar provisions do not apply. A competitor ordinarily does not need a 505(b)(2) application unless it introduces a clinically meaningful change that prevents reliance on the standard ANDA pathway.

Which companies are challenging or competing with Malarone?

Competition comes primarily from generic manufacturers rather than biosimilar developers. The U.S. generic market has included manufacturers such as Glenmark, Apotex, Sandoz, Lupin, and Zydus, among others, depending on strength, market date, and current marketing status.

The competitive field has several layers:

U.S. generic tablet suppliers

These companies compete on:

• Wholesale acquisition cost
• Contract-pharmacy access
• Retail and mail-order distribution
• Supply continuity
• Product availability before travel seasons
• Pediatric strength coverage
• FDA inspection history
• Authorized distributor relationships

International suppliers

Outside the United States, products are supplied by multinational and regional manufacturers under national approvals, WHO-related procurement systems, and country-specific antimalarial programs. The reference brand may retain stronger recognition in travel medicine even where generic tablets are available.

Alternative antimalarials

Malarone competes clinically with doxycycline, mefloquine, tafenoquine, and other antimalarial regimens. These products differ in dosing frequency, contraindications, adherence, psychiatric or gastrointestinal tolerability, pregnancy restrictions, and geographic suitability.

How strong is the Malarone formulation patent estate?

The formulation estate is commercially weaker than a current composition-of-matter estate because generic products can enter using conventional immediate-release technology. The main residual protection risk is not basic excipient selection. It is the possibility of narrower claims covering:

• Specific particle-size distributions
• Solid dispersions
• Surfactant ratios
• Modified-release systems
• Pediatric dosage forms
• Taste-masked formulations
• Manufacturing processes
• Stability-enhancing packaging
• Alternative delivery systems

These claims may affect a particular product design without preventing all generic tablets. Their value depends on claim scope, validity, prosecution history, freedom-to-operate results, and whether the claims are listed in the Orange Book.

For a new entrant, the strongest formulation strategy is usually a non-infringing immediate-release product with demonstrated bioequivalence, supported by a differentiated pediatric or global-health format where commercially justified.

Are Paragraph IV challenges relevant to Malarone?

Paragraph IV challenges were relevant during the period when listed patents could have blocked ANDA approval. They are not the central commercial issue for ordinary current entry because the principal Malarone exclusivity period has expired and generic products are already marketed.

A current applicant still needs to evaluate:

• Any unexpired Orange Book-listed patents
• Patent-use codes
• Declaratory-judgment exposure
• Product-specific formulation patents
• Manufacturing-process claims
• Contract-manufacturing confidentiality risks
• Litigation triggered by a new delivery system

A conventional tablet that does not rely on a protected formulation is less likely to create significant patent litigation exposure than a controlled-release, taste-masked, or particle-engineered product.

What FDA regulatory pathway applies to a Malarone generic?

An ANDA is the most commercially efficient route for a conventional atovaquone/proguanil tablet. The applicant must generally establish:

• Pharmaceutical equivalence
• Comparable dosage form and strength
• Bioequivalence
• Manufacturing quality
• Stability
• Impurity control
• Dissolution performance
• Labeling consistency

The food effect is a central bioequivalence consideration. The applicant should characterize fed and fasted performance where required by FDA guidance and product-specific expectations. Atovaquone exposure may be sensitive to meal composition, particularly fat content, making study design and meal standardization important.[1,4]

A 505(b)(2) route may be appropriate for a suspension, dispersible product, or other dosage form that cannot rely fully on the reference product’s safety and efficacy findings. It offers flexibility but normally requires more clinical and regulatory justification than an ANDA.

What commercial opportunities exist in Malarone excipients?

The most attractive opportunities are not generic substitution of one standard excipient for another. They are integrated formulation and supply-chain solutions.

Pediatric and traveler-health products

A palatable dispersible tablet or dry suspension could command a premium over standard tablets if it materially improves administration and adherence. Travel clinics, pediatric practices, pharmacies, and online travel-health providers are natural channels.

Global-health procurement

A heat-stable, moisture-resistant, compact product can reduce distribution cost and wastage in malaria-endemic regions. A dry powder, dispersible tablet, or low-cost film-coated tablet may be more commercially useful than a sophisticated lipid formulation.

Excipient supply and co-processing

Suppliers can create value through:

• Co-processed microcrystalline cellulose and disintegrant systems
• Low-dust surfactant premixes
• Better-flowing direct-compression grades
• Taste-masking excipient platforms
• Moisture-barrier film-coating systems
• Excipient systems optimized for micronized atovaquone

The buyer’s value proposition is reduced formulation-development time, improved scale-up, and lower dissolution variability.

Contract development and manufacturing

CDMOs can offer integrated services covering:

• Atovaquone particle engineering
• Blend and granulation development
• Tablet compression
• Film coating
• Pediatric dosage-form development
• Bioequivalence batch manufacture
• Stability packaging
• Global regulatory support

The strongest commercial position is likely to come from a platform that addresses both atovaquone dissolution and pediatric administration rather than from a single low-cost excipient.

How does Malarone compare with competing antimalarial products?

Product	Formulation and commercial consideration
Malarone	Daily prophylaxis; short post-travel continuation; atovaquone food effect; higher tablet cost historically
Doxycycline	Low-cost generic; daily dosing; tolerability and sun-sensitivity concerns
Mefloquine	Weekly dosing; neuropsychiatric and tolerability concerns limit some use
Tafenoquine	Longer-acting option in selected settings; requires specific patient screening and regulatory compliance
Chloroquine	Geographic resistance limits use
Artemisinin-based therapies	Important for treatment of malaria, but not interchangeable with routine travel prophylaxis

Malarone’s commercial differentiation is convenience, short continuation after travel, and a generally favorable tolerability profile. Its weaknesses are cost, food-dependent atovaquone exposure, and the need for multiple tablets in treatment dosing.

What generic launch risks exist?

The principal risks are technical and commercial rather than exclusivity-based.

Technical risks

• Failure to match atovaquone dissolution
• Food-effect differences
• Poor content uniformity
• Inadequate pediatric palatability
• Scale-up changes in granule density
• Excipient lot variability
• Moisture-driven degradation or dissolution drift

Commercial risks

• Low reimbursement pricing
• Seasonal demand concentration
• Travel-market dependence
• Stock-outs during malaria outbreaks
• Excessive reliance on one API supplier
• Limited differentiation between generic tablets
• Procurement pressure in public-health channels

Atovaquone API quality and particle engineering can be more important than the nominal excipient bill of materials. A low-cost excipient substitution that causes a dissolution failure can eliminate the expected margin advantage.

What revenue exposure does Malarone represent?

Public companies generally do not report Malarone revenue as a separate line item. The original brand’s revenue exposure has declined because generic competition is established and the product is mature. Current opportunity is therefore more likely to arise from:

• Generic volume
• Pediatric products
• Travel-clinic distribution
• Private-label supply
• Government procurement
• Regional licensing
• CDMO manufacturing
• Excipient and formulation platforms

Revenue is seasonal and geographically concentrated. Demand tends to rise before major travel periods and during outbreaks or changes in malaria-risk guidance. A manufacturer should plan inventory around travel cycles while maintaining sufficient supply flexibility for public-health demand.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barriers are process control and bioequivalence reproducibility. A conventional tablet is technically accessible, but reliable commercial production requires control over:

• Atovaquone particle size
• API deagglomeration
• Surfactant distribution
• Blend segregation
• Compression force
• Tablet porosity
• Film-coating weight gain
• Packaging moisture ingress
• Long-term dissolution stability

Manufacturing-process patents may still matter for a particular particle-engineering or dispersion technology. Trade secrets can be more relevant than patents where the competitive advantage comes from milling conditions, blending order, granulation endpoint, or coating parameters.

Geographic coverage also matters. FDA approval does not establish approval in Europe, Japan, Canada, Australia, or malaria-endemic countries. Each market may impose distinct requirements for bioequivalence, stability zones, labeling, pediatric presentation, pharmacovigilance, and local registration.

Key Takeaways

• Malarone is an atovaquone/proguanil fixed-dose combination with expired primary exclusivity and established generic competition.
• Atovaquone’s poor solubility and food-dependent absorption make wetting, particle engineering, dissolution, and manufacturing control the central formulation issues.
• The reference formulation uses poloxamer 188, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, povidone, sodium starch glycolate, magnesium stearate, and conventional film-coating excipients.
• A conventional immediate-release tablet is generally the lowest-risk generic opportunity.
• Pediatric dispersible tablets, dry suspensions, chewable products, and taste-masked formats offer greater differentiation but carry higher regulatory and technical risk.
• Current commercial value is concentrated in generic supply, pediatric usability, global-health procurement, travel medicine, excipient systems, and CDMO services.
• Patent risk is lower for a standard non-infringing tablet and higher for particle-engineered, taste-masked, modified-release, or novel pediatric products.
• FDA Orange Book and current product-specific patent records should govern any live freedom-to-operate or Paragraph IV assessment.

FAQs

Can poloxamer 188 be replaced in a generic Malarone formulation?

Yes, but replacement can alter atovaquone wetting, dissolution, bioequivalence, and food-effect behavior. The substitute requires comparative formulation and dissolution data.

Is a liquid Malarone product commercially attractive?

It can be attractive for pediatric and low-swallowability markets, but suspension stability, taste masking, preservative control, reconstitution, and dose accuracy increase development cost.

Does Malarone have biosimilar competition?

No. Malarone is a small-molecule drug. Competing products are generics regulated through ANDA or, for materially different dosage forms, potentially a 505(b)(2) pathway.

Which excipient offers the greatest formulation leverage for atovaquone?

A surfactant or wetting system, including poloxamer-based technology, often offers the greatest initial leverage. Its performance must be evaluated with particle size, granulation, tablet porosity, and dissolution conditions.

Can an excipient supplier obtain meaningful protection around a Malarone formulation?

Potentially. Protection may arise from a specific excipient ratio, particle-engineering process, solid dispersion, taste-masking system, dosage form, or manufacturing method. Broad claims covering ordinary tablet excipients are less likely to create durable exclusivity.

References

1. U.S. Food and Drug Administration. (2023). Malarone (atovaquone and proguanil hydrochloride) tablets: Prescribing information.
2. National Library of Medicine. (2024). DailyMed: Malarone, atovaquone and proguanil hydrochloride tablet.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2015). Draft guidance on atovaquone and proguanil hydrochloride tablets: Product-specific bioequivalence recommendations.